Abstract: A chimeric antigen receptor (CAR), containing a BCMA (B cell maturation antigen) binding domain. The BCMA binding domain includes an antibody or an antigen-binding fragment of an antibody that specifically binds to BCMA. The antibody contains a heavy-chain complementarity determining region 3 (HCDR3), a heavy-chain complementarity determining region 2 (HCDR2), and a heavy-chain complementarity determining region 1 (HCDR1). The HCDR3 contains an amino acid sequence as set forth in SEQ ID NO: 25, the HCDR2 contains an amino acid sequence as set forth in SEQ ID NO: 41, and the HCDR1 contains an amino acid sequence as set forth in SEQ ID NO: 21.

Abstract: This disclosure relates to anti-CD40 (TNF Receptor Superfamily Member 5) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: This disclosure relates to anti-human OX40 (TNF Receptor Superfamily Member 4, or TNFRSF4) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: This disclosure relates to anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4 or CTLA-4) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: A tracking type flexible photovoltaic bracket is provided, including photovoltaic assemblies, pillars, a driving member, direction-changing mechanisms, and two pulling ropes. Each of the pillars is disposed with a double-rope grooved wheel. The driving member is configured to drive the double-rope grooved wheel arranged on an end of the driving member to rotate. The direction-changing mechanisms are arranged corresponding ones of the pillars in one-to-one manner. Each of the direction-changing mechanisms includes a worm gear assembly and a curved plate assembly. Each of the corresponding ones of the pillars is rotatably connected with the worm gear assembly and the curved plate assembly, and a bottom of the curved plate assembly is disposed with a gear rack. First ends and second ends of the two pulling ropes are wound on the respective double-rope grooved wheels being respectively located on the first ends and the second ends.

Abstract: A media item of a content sharing platform is identified. A subset of comments in a comment section presented with the media item is identified. A comment score for each comment in the subset of comment is determined. The comment score indicates comment attributes associated with a respective comment in the subset of comments. At least one comment section score for the media item is determined based on comment scores of the subset of comments. One or more media item attributes of the media item are determined based on the at least one comment section score. The media item is associated with the one or more media item attributes. The media one or more media item attributes are indicative of whether a ranking of the media item is to be adjusted.

Abstract: This disclosure relates to anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4 or CTLA-4) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD3e (T-cell surface glycoprotein CD3 epsilon chain), and methods of use thereof.

Abstract: This disclosure relates to anti-human OX40 (TNF Receptor Superfamily Member 4, or TNFRSF4) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: This disclosure relates to anti-TNFRSF9 (tumor necrosis factor receptor superfamily member 9) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: The invention discloses a method, a system and a storage medium for solid-phase concentration correction of a lithium battery.

Abstract: This disclosure relates to genetically modified animal expressing human or chimeric (e.g., humanized) GLP1R, and methods of use thereof.

Abstract: The invention provides method, apparatus and storage medium for adjusting the charging-discharging efficiency ratio of an energy storage power station.

Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD47, and methods of use thereof.

Abstract: The present disclosure relates to genetically modified non-human animals that express a fusion protein including B2M and FcRn, and methods of use thereof. In some embodiments, the animals can have a B-NDG background. In some embodiments, the endogenous B2M gene is knocked out in the animals.

Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD276, and methods of use thereof.

Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD38, and methods of use thereof.

Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) major histocompatibility complex (MHC) protein complex, and methods of use thereof.

Abstract: This disclosure relates to genetically modified immunodeficient animals which express a human or chimeric (e.g., humanized) SIRP? and/or human or chimeric (e.g., humanized) CD47, and methods of use thereof.

Abstract: Provided are a humanized transgenic non-human animal, especially a rodent, in particular a transgenic mouse containing a human interleukin 17A (IL-17A) gene, a human gene 17RA (IL-17RA) and/or a human TNF-alpha gene, and a preparation method therefor and the use thereof.